Alzinova Valuation

Is ALZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALZ?

Key metric: As ALZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALZ. This is calculated by dividing ALZ's market cap by their current revenue.
What is ALZ's PS Ratio?
PS Ratio	19.6x
Sales	SEK 17.39m
Market Cap	SEK 340.61m

ALZ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	18x
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ALZ's PS Ratio compare to its peers?

The above table shows the PS ratio for ALZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	25.4x
IVACC Intervacc	19.2x	104.9%	SEK 192.4m
SANION Saniona	31.5x	35.3%	SEK 655.6m
BIOVIC B Biovica International	28.8x	81.7%	SEK 212.3m
ACOU AcouSort	22x	59.1%	SEK 184.4m
ALZ Alzinova	19.6x	17.7%	SEK 340.6m

Price-To-Sales vs Peers: ALZ is good value based on its Price-To-Sales Ratio (19.6x) compared to the peer average (25.4x).

Price to Sales Ratio vs Industry

How does ALZ's PS Ratio compare vs other companies in the SE Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
XBRANE Xbrane Biopharma	1.4x	61.1%	US$24.82m
SPRINT Sprint Bioscience	2.1x	27.6%	US$11.18m
PMDS PMD Device Solutions	0.9x	62.0%	US$3.23m
GEAN Genetic Analysis	1.3x	n/a	US$2.28m

7 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ALZ is expensive based on its Price-To-Sales Ratio (19.6x) compared to the Swedish Biotechs industry average (13.2x).

Price to Sales Ratio vs Fair Ratio

What is ALZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	19.6x
Fair PS Ratio	2.9x

Price-To-Sales vs Fair Ratio: ALZ is expensive based on its Price-To-Sales Ratio (19.6x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

-2.9%

n/a

Camurus

SEK 32.6b

A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.

CAMX

SEK 553.50

0.6%

22.2%

Corline Biomedical

SEK 137.5m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.40

-7.5%

-48.2%